Although it is unlikely that sulfonylureas will be used as a therapeutic option for treating patients with mitochondrial diseases due to their control over insulin secretion, this study reveals that IRE1α and p38 inhibitors may serve as more practical compounds in the future treatment of these disorders. This evidence concerns the gene ERN1 and inborn mitochondrial metabolism disorder.